Incorporating estimands into clinical trial statistical analysis plans.
Estimand
ICH
statistical analysis plan
Journal
Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
9
3
2022
medline:
18
6
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
International Council for Harmonisation (ICH) E9 A table format was used to create a template for inclusion in SAPs that satisfies ICH E9 (R1) guidance to align statistical analysis to the estimand. The template provides a consistent structure for presentation of estimands and the associated analysis, and is applicable to a wide range of trial designs. We illustrate use of the template with a hypothetical clinical trial in HIV-1. The estimand-to-analysis table template starts with the study objective describing the clinical question of interest as written in the trial protocol. The remainder of the table describes each attribute of the estimand (treatment, target population, variable, intercurrent events, and population-level summary) in the left column (ESTIMAND), while the right column describes how each attribute will be handled using the data collected in the clinical trial (ANALYSIS). The template was applied to a hypothetical, early-phase single-arm trial, modeled after a pediatric trial in HIV, where the objective was to determine the safety of a new antiretroviral drug as part of a combination antiretroviral treatment regimen in the pediatric population. Three intercurrent events were illustrated in the table: death, premature treatment discontinuation before 24 weeks, and pregnancy. An estimand-to-analysis table from a grant application that addresses the primary objective of a placebo-controlled randomized trial is also presented to demonstrate an alternative usage. We found the template to be useful in study design, providing a snapshot of the objective, target population, potential intercurrent events, analysis plan, and considerations for missing data in one place and facilitating discussion among stakeholders. The proposed standardized presentation of estimand attributes and analysis considerations in SAPs will provide guidance to SAP authors and consistency across studies to facilitate reviews.
Sections du résumé
BACKGROUND
International Council for Harmonisation (ICH) E9
METHODS
A table format was used to create a template for inclusion in SAPs that satisfies ICH E9 (R1) guidance to align statistical analysis to the estimand. The template provides a consistent structure for presentation of estimands and the associated analysis, and is applicable to a wide range of trial designs. We illustrate use of the template with a hypothetical clinical trial in HIV-1.
RESULTS
The estimand-to-analysis table template starts with the study objective describing the clinical question of interest as written in the trial protocol. The remainder of the table describes each attribute of the estimand (treatment, target population, variable, intercurrent events, and population-level summary) in the left column (ESTIMAND), while the right column describes how each attribute will be handled using the data collected in the clinical trial (ANALYSIS). The template was applied to a hypothetical, early-phase single-arm trial, modeled after a pediatric trial in HIV, where the objective was to determine the safety of a new antiretroviral drug as part of a combination antiretroviral treatment regimen in the pediatric population. Three intercurrent events were illustrated in the table: death, premature treatment discontinuation before 24 weeks, and pregnancy. An estimand-to-analysis table from a grant application that addresses the primary objective of a placebo-controlled randomized trial is also presented to demonstrate an alternative usage.
CONCLUSION
We found the template to be useful in study design, providing a snapshot of the objective, target population, potential intercurrent events, analysis plan, and considerations for missing data in one place and facilitating discussion among stakeholders. The proposed standardized presentation of estimand attributes and analysis considerations in SAPs will provide guidance to SAP authors and consistency across studies to facilitate reviews.
Identifiants
pubmed: 35257600
doi: 10.1177/17407745221080463
pmc: PMC9232859
mid: NIHMS1775846
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-291Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068616
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Références
Stat Biopharm Res. 2020 Jul 6;12(4):399-411
pubmed: 34191971
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
Clin Trials. 2019 Aug;16(4):339-344
pubmed: 30977390
Int J Obes (Lond). 2021 May;45(5):923-933
pubmed: 33462358
N Engl J Med. 2012 Oct 4;367(14):1355-60
pubmed: 23034025
PLoS Med. 2019 Mar 22;16(3):e1002767
pubmed: 30901331
Ther Innov Regul Sci. 2020 Mar;54(2):324-341
pubmed: 32072573
Lancet. 2021 Mar 13;397(10278):971-984
pubmed: 33667417
JAMA. 2017 Dec 19;318(23):2337-2343
pubmed: 29260229
Trials. 2020 Jul 23;21(1):671
pubmed: 32703247
Am Heart J. 2019 Jun;212:23-35
pubmed: 30928825
Pharm Stat. 2021 Mar;20(2):314-323
pubmed: 33098267